{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:48Z","timestamp":1781568048392,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ijantimicag.2017.03.024","type":"journal-article","created":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T07:46:09Z","timestamp":1499499969000},"page":"371-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinical benefits of antimicrobial de-escalation in adults with community-onset monomicrobial Escherichia coli , Klebsiella species and Proteus mirabilis bacteremia"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4949-2742","authenticated-orcid":false,"given":"Ching-Chi","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiun-Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Pin","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yuan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Jen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chien","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0010","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00003246-200107000-00002","article-title":"Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care","volume":"29","author":"Angus","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0015","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/jac\/dks475","article-title":"Outcome of inadequate empirical antibiotic therapy in emergency department patients with community-onset bloodstream infections","volume":"68","author":"Chen","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jmii.2013.08.004","article-title":"Clinical impact of Gram-negative nonfermenters on adults with community-onset bacteremia in the emergency department","volume":"48","author":"Chiu","year":"2015","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0025","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJMoa010307","article-title":"Early goal-directed therapy in the treatment of severe sepsis and septic shock","volume":"345","author":"Rivers","year":"2001","journal-title":"New Eng J Med"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0030","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/01.CCM.0000298158.12101.41","article-title":"Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008","volume":"36","author":"Dellinger","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0035","doi-asserted-by":"crossref","first-page":"S527","DOI":"10.1097\/01.CCM.0000142983.15421.11","article-title":"Use of corticosteroid therapy in patients with sepsis and septic shock: an evidence-based review","volume":"32","author":"Keh","year":"2004","journal-title":"Crit Care Med"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2017.03.024_bib0040","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/590061","article-title":"Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front","volume":"47","author":"Kollef","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0045","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/jac\/43.4.459","article-title":"A review of the role of antibiotic policies in the control of antibiotic resistance","volume":"43","author":"Gould","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0050","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1097\/01.CCM.0000241151.25426.D7","article-title":"Before-after study of a standardized hospital order set for the management of septic shock","volume":"34","author":"Micek","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0055","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/01.ccx.0000244126.84989.a2","article-title":"De-escalation therapy in ventilator-associated pneumonia","volume":"12","author":"Niederman","year":"2006","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0060","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1378\/chest.122.6.2183","article-title":"Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU","volume":"122","author":"Hoffken","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0065","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.diagmicrobio.2015.03.004","article-title":"Impact of antimicrobial strategies on clinical outcomes of adults with septic shock and community-onset Enterobacteriaceae bacteremia: de-escalation is beneficial","volume":"82","author":"Lee","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0070","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cmi.2016.05.023","article-title":"Antibiotic de-escalation for bloodstream infections and pneumonia: systematic review and meta-analysis","volume":"22","author":"Paul","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0075","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0080","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02174-16","article-title":"Clinical benefit of appropriate empirical fluoroquinolone therapy for adults with community-onset bacteremia in comparison with third-generation cephalosporin therapy","volume":"61","author":"Lee","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0085","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ijantimicag.2016.09.015","article-title":"Propensity score-matched analysis comparing the therapeutic efficacies of cefazolin and extended-spectrum cephalosporins as appropriate empirical therapy in adults with community-onset Escherichia coli, Klebsiella spp. and Proteus mirabilis bacteraemia","volume":"48","author":"Hsieh","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0090","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/0002-9343(55)90192-3","article-title":"Complications of antibiotic therapy","volume":"18","author":"Von Oettingen","year":"1955","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0095","series-title":"Performance standards for antimicrobial susceptibility testing; approved standard. Twenty-six informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2016"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0100","series-title":"Performance standards for antimicrobial susceptibility testing; approved standard. Nineteenth informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2009"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0105","series-title":"Selected pharmacologic faetures of antimicrobial agents","first-page":"78","author":"Gilbert","year":"2009"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0110","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0895-4356(93)90024-U","article-title":"Comorbidity of chronic diseases in general practice","volume":"46","author":"Schellevis","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0115","first-page":"135","article-title":"Gram-negative bacteremia","volume":"19","author":"McCabe","year":"1974","journal-title":"Adv Intern Med"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7326\/0003-4819-140-1-200401060-00008","article-title":"International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections","volume":"140","author":"Paterson","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0125","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An Introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archsurg.1993.01420130087014","article-title":"Antimicrobial prophylaxis for surgical wounds. Guidelines for clinical care","volume":"128","author":"Page","year":"1993","journal-title":"Arch Surg"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0135","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","article-title":"Osteomyelitis","volume":"364","author":"Lew","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0140","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/497143","article-title":"Practice guidelines for the diagnosis and management of skin and soft-tissue infections","volume":"41","author":"Stevens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0145","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003495-197917040-00001","article-title":"Cefuroxime: a review of its antibacterial activity, pharmacological properties and therapeutic use","volume":"17","author":"Brogden","year":"1979","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0150","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/cid\/cir031","article-title":"Subcommittee on Antimicrobial Susceptibility Testing of the C, Laboratory Standards I. Cefazolin and enterobacteriaceae: rationale for revised susceptibility testing breakpoints","volume":"52","author":"Turnidge","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.03.024_bib0155","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/ageing\/16.4.201","article-title":"The atypical presentation of infection in old age","volume":"16","author":"Berman","year":"1987","journal-title":"Age Ageing"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T20:50:57Z","timestamp":1602449457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917302534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0924857917302534"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.03.024","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical benefits of antimicrobial de-escalation in adults with community-onset monomicrobial Escherichia coli, Klebsiella species and Proteus mirabilis bacteremia","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}